143 related articles for article (PubMed ID: 37170613)
21. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
22. Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib.
Watts C; Nadori K
J Oncol Pharm Pract; 2023 Jun; 29(4):962-966. PubMed ID: 36000297
[TBL] [Abstract][Full Text] [Related]
23. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S; Palacova M; Łacko A; Timcheva C; Gal-Yam EN; Papazisis K; Beniak J; Kudela P; Rubovszky G
Radiol Oncol; 2022 May; 56(2):238-247. PubMed ID: 35575587
[TBL] [Abstract][Full Text] [Related]
24. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
25. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
26. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Wong V; de Boer R; Baron-Hay S; Blum R; Boyle F; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott L; Nottage M; Tafreshi A; Tsoi D; Uccellini A; Hong W; Gibbs P; Lok SW
Clin Breast Cancer; 2022 Dec; 22(8):792-800. PubMed ID: 36151018
[TBL] [Abstract][Full Text] [Related]
27. Vortex keratopathy associated with ribociclib.
Türkel A; Özdoğan S; Yekedüz E; Şeyran E; Karaçin C; Ateş Ö
J Oncol Pharm Pract; 2023 Jan; 29(1):230-232. PubMed ID: 35570741
[TBL] [Abstract][Full Text] [Related]
28. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
29. Ribociclib-induced liver injury: a case report.
Schaeffer S; Lutz C; Dobbie M; Terracciano LM; Matter M; Vosbeck J; Heim MH; Bernsmeier C
Front Oncol; 2023; 13():1256783. PubMed ID: 38107071
[TBL] [Abstract][Full Text] [Related]
30. CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Meynard L; Grellety T
Breast J; 2020 Feb; 26(2):255-257. PubMed ID: 31495008
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
De Laurentiis M; Caputo R; Mazza M; Mansutti M; Masetti R; Ballatore Z; Torrisi R; Michelotti A; Zambelli A; Ferro A; Generali D; Vici P; Coltelli L; Fabi A; Marchetti P; Ballestrero A; Spazzapan S; Frassoldati A; Sarobba MG; Grasso D; Zamagni C
Target Oncol; 2022 Nov; 17(6):615-625. PubMed ID: 36152144
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
Malik AA; Abbas H; Oo ZM; Lim Z
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34312131
[TBL] [Abstract][Full Text] [Related]
33. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Yap YS; Chiu J; Ito Y; Ishikawa T; Aruga T; Kim SJ; Toyama T; Saeki T; Saito M; Gounaris I; Su F; Ji Y; Han Y; Gazdoiu M; Masuda N
Cancer Sci; 2020 Sep; 111(9):3313-3326. PubMed ID: 32619077
[TBL] [Abstract][Full Text] [Related]
34. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Hart L; Campone M; Petrakova K; Winer EP; Janni W; Conte P; Cameron DA; André F; Arteaga CL; Zarate JP; Chakravartty A; Taran T; Le Gac F; Serra P; O'Shaughnessy J
N Engl J Med; 2022 Mar; 386(10):942-950. PubMed ID: 35263519
[TBL] [Abstract][Full Text] [Related]
35. Ribociclib in newly diagnosed hepatitis B infection: A case report.
Di Costanzo F; Carrano S; Iengo G; Cefaliello A; Cossiga V; Morisco F; Giuliano M; De Angelis C; Arpino G
Front Oncol; 2023; 13():1184952. PubMed ID: 37361578
[TBL] [Abstract][Full Text] [Related]
36. Ribociclib plus fulvestrant in the treatment of breast cancer.
Neven P; Sonke GS; Jerusalem G
Expert Rev Anticancer Ther; 2021 Jan; 21(1):93-106. PubMed ID: 33085548
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN
Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report.
Sun M; Cai L; Chen M
Medicine (Baltimore); 2023 Jun; 102(24):e33975. PubMed ID: 37327257
[TBL] [Abstract][Full Text] [Related]
40. Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E
J Med Case Rep; 2014 Dec; 8():417. PubMed ID: 25491149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
